Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
In-Depth Reviews
You have accessRestricted Access

Heart Failure and Nephropathy: Catastrophic and Interrelated Complications of Diabetes

Richard E. Gilbert, Kim Connelly, Darren J. Kelly, Carol A. Pollock and Henry Krum
CJASN March 2006, 1 (2) 193-208; DOI: https://doi.org/10.2215/CJN.00540705
Richard E. Gilbert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kim Connelly
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Darren J. Kelly
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carol A. Pollock
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henry Krum
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Abstract

Heart failure (HF) is a major contributor to poor quality of life, a leading cause of hospitalization, and cause of premature death. Both kidney disease and diabetes are major and independent risk factors for the development of heart failure, such that individuals with diabetic nephropathy are at especially high risk. Such patients not only are likely to have coronary artery disease and hypertension but also are likely to have diabetic cardiomyopathy, a distinct pathologic entity that is more closely associated with the microvascular than the macrovascular complications of diabetes. In addition to a better understanding of the epidemiology of HF, advances in noninvasive imaging have highlighted the importance of early cardiac dysfunction in diabetes and the high prevalence of HF with preserved left ventricular systolic function. Although significant renal dysfunction is usually an exclusion criterion in HF trials, diabetes is often a prespecified subgroup so that subanalyses of large multicenter clinical trials do provide some guidance in therapeutic decision-making. However, further therapies for both HF and nephropathy in diabetes clearly are needed, and a number of new therapeutic strategies that target both disorders have already entered the clinical arena.

The global burden of diabetes, estimated to reach 366 million by 2025 (1), brings with it the potential for a catastrophic increase in the prevalence of kidney and cardiovascular disease. Although the increased mortality in patients with diabetes traditionally has been attributed to coronary artery disease, more recent studies have emphasized the importance of chronic heart failure (HF) as a common and deadly comorbidity (2), to which the patient with nephropathy, even in its earliest stages, is especially prone (3). The recognition of such a link between HF and kidney failure in diabetes is supported not only by epidemiologic data but also by shared pathogenetic mechanisms that underlie the development of both disorders and give rise to common therapeutic approaches aimed at slowing their progression.

The studies discussed in this review were based on a search of the Ovid database using the following search terms: Heart failure, diabetes, nephropathy, kidney disease, proteinuria, diastolic dysfunction, and clinical trial.

Epidemiology

Chronic HF is a major and growing public health problem in industrialized nations. In the United States, for instance, the prevalence of HF was 4.9 million in 2002 and is estimated to reach 10 million by 2007 (4), such that at age 40, there will be an approximate one in five lifetime risk for developing new-onset HF in both men and women (5). Despite the advances in therapy, mortality in HF remains high, with a 5-yr age-adjusted death rate of 59% in men and 45% in women (6). Moreover, in addition to its high mortality, HF accounts for considerable morbidity as the leading cause of hospitalizations in those who are older than 65 yr, with almost 1 million admissions each year, making it the US Health Care Financing Administration’s largest, most expensive diagnosis-related group (7), contributing to the estimated direct and indirect costs of HF in the US of $27.9 billion per year (8).

Diabetes and HF

The association between the diabetes and HF was first reported in the Framingham study in 1971, in which the high prevalence of diabetes (14% of men and 26% of women) among patients with HF was noted (9) such that the risk for development of HF in patients with diabetes was increased two- and five-fold in men and women, respectively (10). Similar findings also have been reported by a number of other community-based epidemiologic studies, all of which noted diabetes as an independent risk factor for the development of HF (11–13), and identifying age, diabetes duration, insulin use, ischemic heart disease, and elevated serum creatinine as markers of risk among patients with diabetes (14).

In clinical trials of HF, in which participants are frequently younger than in community-based studies, diabetes is a noted comorbidity in between 10 and >30% of participants (2). Indeed, the increased risk for HF conferred by diabetes is especially marked in younger patients (45 to 65 yr), for whom the prevalence of HF is increased five- to eight-fold compared with nondiabetic individuals (Figure 1).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Age-dependent prevalence of heart failure (HF) in patients with and without diabetes (14). Adapted from www.hypertensiononline.org.

Until very recently, HF in diabetes has received little attention, being omitted frequently in the teaching of lists of diabetic complications, making it “the frequent, forgotten, and often fatal complication of diabetes,” as noted by Bell (15). Indeed, the likelihood of developing HF is similar to the risk for the other micro- and macrovascular problems of the disease. For instance, in the UK Prospective Diabetes Study (UKPDS), the development of HF was examined over a 10-yr period in almost 4000 community-based, middle-aged, patients with type 2 diabetes (16,17). The rate of hospitalization for HF was 3.0 to 8.1 per 1000 patient-years (depending on assigned treatment group), similar to that of nonfatal myocardial infarction (MI), nonfatal stroke, and renal failure at 7.5 to 9.5, 4.0 to 8.9, and 0.6 to 2.3 per 1000 patient-years, respectively, in the same study.

Kidney Failure and HF

Functioning in tandem, the kidney and the heart provide the physiologic regulation of extracellular fluid volume (ECFV), natriuresis, BP, cardiac output, and GFR. The intimate relationship between these two organ systems is also apparent in disease states in which renal and cardiac dysfunction frequently coexist (Figure 2), reflecting common factors in their pathogeneses that include, in addition to diabetes, hypertension, fluid overload, aging, left ventricular hypertrophy, and atherosclerotic vascular disease.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

HF rates in patients who were receiving dialysis and in Medicare recipients with and without chronic kidney disease (CKD) (155).

Even mild degrees of renal impairment are associated with an enhanced risk for HF (18) that increases with worsening renal function (19). By the time they reach ESRD, approximately 40% of patients who are on either hemodialysis or peritoneal dialysis have overt HF (20), where it is associated with an especially poor prognosis (20) such that for patients who start ESRD therapy with HF at baseline, the median survival is 36 mo compared with 62 mo in patients without HF (21). Conversely, renal dysfunction (Cockroft-Gault calculated creatinine clearance <60 ml/min) also is a common finding, noted in 20 to 36% of patients with HF (22), for whom its presence is associated with increased mortality, mostly as a consequence of HF progression (22).

HF in Incipient Diabetic Nephropathy

Microalbuminuria (incipient nephropathy) is a well-recognized predictor of increased mortality and cardiovascular risk in diabetes (23–26); however, its value as a predictor of HF has only recently been established. In the Heart Outcomes Prevention Evaluation (HOPE) Study and MICRO (Microalbuminuria, Cardiovascular and Renal Outcomes) HOPE substudy, patients who were at increased cardiovascular risk but without HF at baseline were evaluated over a median of 4.5 yr (27,28). In these studies, the presence of microalbuminuria at baseline (albumin/creatine ratio ≥2 mg/mmol), noted in 32.6% of participants with diabetes, conferred a 3.7-fold increased risk for hospitalization for HF (3). Indeed, the DIABHYCAR (type 2 Diabetes, Hypertension, Cardiovascular events and Ramipril) Study noted that the presence of HF in the setting of an elevated urinary albumin concentration portends a particularly poor prognosis, with a 10-fold increase in mortality compared with patients who also have a high urinary albumin concentration but not HF (29).

HF in Overt Diabetic Nephropathy

The Irbesartan Diabetic Nephropathy Trial (IDNT) studied patients with type 2 diabetic nephropathy, an elevated baseline serum creatinine (1.0 to 3.0 mg/dl in women, 1.2 to 3.0 mg/dl in men), overt proteinuria, and hypertension, excluding patients with symptomatic HF because of their absolute requirement for an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) (30). Despite this, over a median follow-up period of 2.6 yr, hospitalization for HF was the most commonly reported cardiovascular event, occurring in 13% of study participants, compared with MI (6%) and stroke (4%) (31). Likewise, the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study, with similar entry and exclusion criteria, reported HF hospitalizations in 14% of patients (32).

Proteinuria

The magnitude of proteinuria not only is an important marker of progressive renal dysfunction but also predicts an increased likelihood of cardiovascular events, including HF (33). For instance, in the RENAAL study, baseline proteinuria was found to be the strongest predictor of HF (34), with an almost linear relationship between the two such that an increase of 1.0 g/g proteinuria was associated with 26% (95% confidence interval 18 to 34%) risk for HF (34) (Figure 3). Furthermore, the extent to which proteinuria was reduced in the trial also had an impact on the likelihood of HF events, even after adjustment for other risk markers (Figure 3), leading the authors to suggest that reduction in albuminuria may achieve cardiovascular benefits beyond BP lowering (34).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Hazard ratio for HF as a function of baseline albuminuria (left) and percentage change in albuminuria at 6 mo (right) in Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan study participants (34).

GFR

As with proteinuria, the extent to which GFR is impaired also is an important predictor of HF in diabetic nephropathy (35) such that in the RENAAL Study, the incidence of HF hospitalization increased with tertiles of serum creatinine, rising from 11.1% (lowest tertile; serum creatinine 0.9 to 1.6 mg/dl) through 15.0% (middle tertile; serum creatinine 1.6 to 2.0 mg/dl) to 16.4% (highest tertile; serum creatinine 2.1 to 3.6 mg/dl) (35).

Cause of HF in Diabetes and the “Toxic Triad”

The mechanisms underlying the development of HF in patients with diabetes, particularly those with nephropathy, are multiple and interrelated, including not only the pathophysiologic changes, which develop as a direct consequence of hyperglycemia and of renal dysfunction, but also those related to the common comorbidity of the metabolic syndrome. Such patients exhibit what has been termed a “cardiotoxic triad” of cardiac ischemia, hypertension, and diabetic cardiomyopathy (15), together resulting in a poorly compliant, fibrotic, hypertrophied, and ultimately dysfunctional myocardium.

Coronary Artery Disease

Patients with diabetes characteristically develop premature atherosclerotic coronary artery disease, which often is widespread, is asymptomatic, presents late, and tends to involve multiple and distal coronary segments (36). Furthermore, patients with diabetes develop fewer collateral vessels in response to ischemia (37), possibly reflecting impaired production of or responsiveness to vascular endothelial growth factor (38,39). Not only are patients with diabetes at higher risk for coronary artery disease, but also their outcome after MI is considerably worse than in nondiabetic patients (40,41), as is their response to both percutaneous (42,43) and surgical revascularization (44,45). As might be expected from these findings, patients with diabetes are also two to three times more likely to develop HF after MI, and women with diabetes are at particularly high risk (46).

Painless ischemia is very common in patients with diabetes such that dyspnea may be both the presenting symptom of acute ischemia and the result of chronic, incremental loss of myocardium (47). Because patients with diabetes and HF may derive benefit not only from medical anti-anginal therapy but also from percutaneous or surgical revascularization, investigation for underlying coronary artery disease routinely should be undertaken.

As with diabetes, renal function, even when mildly impaired, also is an important predictor of adverse outcome after MI. For instance, in the Valsartan in Acute Myocardial Infarction Trial (VALIANT), in which patients whose plasma creatinine at entry was >2.5 mg/dl (0.22 mmol/L) were excluded, the likelihood of developing HF increased incrementally with the extent of renal impairment as assessed by estimated GFR, with an approximate three-fold increase of HF in patients with GFR <45 ml/min per 1.73 m2 compared with those whose GFR was >75 ml/min per 1.73 m2 (48). However, the likelihood of previous HF, diabetes, and hypertension also increased with worsening baseline renal function such that it is difficult to assess the impact of the renal dysfunction per se. Nevertheless, the presence of renal dysfunction does identify patients who are at high risk for HF after MI, and it seems likely that this risk might be magnified in the presence of diabetes as a comorbidity.

Diabetic Cardiomyopathy

In 1972, Rubler et al. (49) reported a postmortem case series of four patients with diabetic nephropathy and HF in the absence of valve disease, significant coronary atherosclerosis, hypertension, or alcohol excess. All had advanced HF with pathologic examination revealing cardiac fibrosis and hypertrophy. More recent biopsy-based studies have indicated that cell loss as a result of apoptosis and necrosis of cardiac myocytes and endothelial cells also are prominent features of diabetic cardiomyopathy (50), along with a range of microvascular abnormalities that include capillary microaneurysm formation (51), arteriolar thickening, and reduced capillary density. Together, these histopathologic features of diabetic cardiomyopathy of fibrosis, atrophy, and hypertrophy are similar to those found in the diabetic kidney, where enlarged and sclerotic glomeruli are found among alternately hypertrophied and atrophic tubules surrounded by a fibrotic interstitium.

In addition to the structural changes of fibrosis, apoptosis, and hypertrophy, a number of pathophysiologic perturbations that contribute to the development of diabetic cardiomyopathy also have been elucidated. These include both changes in cardiac myocytes such as altered substrate metabolism and depressed cardiac myocyte energetics as well as extramyocardial abnormalities such as endothelial dysfunction and autonomic neuropathy (52). Although a detailed exposition of these is not possible in this report, the mechanisms that underlie the development of diabetic cardiomyopathy have been the subject of several recent excellent reviews (15,53–55).

Thus, although still the subject of controversy, clinical, histopathologic, and experimental data all support the existence of a diabetic cardiomyopathy as a cause of systolic and diastolic dysfunction and impaired exercise tolerance in patients with diabetes (56). From a clinical perspective, diabetic cardiomyopathy is a diagnosis of exclusion, defined as cardiac dysfunction in a patient with diabetes that cannot be explained by coronary artery disease, hypertension, or other known cardiac disease (56). In many patients with diabetes, diabetic cardiomyopathy will present subclinically as impaired exercise capacity. Although this often is presumed to be a consequence of obesity and aging, echocardiography frequently will identify diastolic dysfunction in such patients. With more advanced disease, patients will present with overt HF and show evidence of diastolic and/or systolic dysfunction on echocardiography.

Hypertension

Hypertension, another risk factor for the development of HF, is common in patients with diabetes and, as would be expected, increases with the severity of nephropathy. Thus, on the basis of a BP >140/90 mmHg or the receipt of antihypertensive therapy, hypertension is present in 71, 90, and 93% of patients with diabetes and normo-, micro-, and macroalbuminuria, respectively (57).

As in nephropathy, the coexistence of hypertension has an important influence on the extent of cardiac injury in diabetes. For instance, in an autopsy-based study that examined the heart of patients with hypertension, diabetes, or both, the extent of cardiac fibrosis was lowest in the heart of patients with hypertension, mid-range in those with diabetes, and highest in hypertensive patients with diabetes and was significantly greater in those with HF (58). More recently, in a biopsy-based study, Frustaci et al. (50) examined cardiac pathology in patients who had diabetes and HF and no evidence of coronary artery disease on angiography, reporting that the extent of fibrosis, apoptosis, and hypertrophy all were greater in hypertensive patients with diabetes compared with those with diabetes alone.

Diabetes and Diastolic and Subclinical Systolic HF

The ability to assess noninvasively cardiac systolic function with left ventriculography and echocardiography has brought with it the realization that approximately 30 to 50% of hospitalizations for HF occur in patients with preserved left ventricular systolic function, mostly as a result of diastolic dysfunction of the left ventricle (59), a condition to which patients with diabetes are especially prone. Although mortality rates for diastolic HF (DHF) are lower than in systolic HF (SHF), particularly in younger (<65 yr) patients (60), hospitalization rates are similar (60). Risk factors for the development of DHF in patients with diabetic nephropathy include in addition to renal dysfunction and diabetes per se, advancing age, hypertension, and coronary artery disease (61).

Diagnosis

Despite its clinical importance, the criteria that are used to make a diagnosis of DHF are still debated. The “gold standard” for the assessment of left ventricular diastolic function requires cardiac catheterization. However, in most cases, this is not practicable and a combination of clinical and noninvasive cardiac imaging techniques are used to make a diagnosis of DHF. For instance, a patient who presents in pulmonary edema would be referred to as having “probable” DHF if left ventricular function, measured within 72 h of presentation, is preserved (left ventricular ejection fraction [LVEF] >0.50), requiring, in addition, evidence of diastolic dysfunction as measured by noninvasive techniques to make a diagnosis of “definite” DHF according to Vasan and Levy (62). Furthermore, an important caveat in the evaluation of a patient who has symptomatic HF and whose systolic function is preserved is that episodic painless cardiac ischemia may cause transient systolic dysfunction, such that the underling diagnosis is ischemic heart disease rather than DHF.

Echocardiography in DHF

The tremendous advances in echocardiography and tissue Doppler imaging over the past 10 yr, particularly with regard to the assessment of diastolic function (63), have witnessed an avalanche of echocardiographic studies performed in asymptomatic patients with diabetes. However, although greatly advancing our knowledge in the area, the parameters detailed in such studies, are not those routinely reported in the clinical setting and thus are not well understood by internists, diabetologists, and nephrologists who commonly treat patients with DHF. Accordingly a brief outline of echocardiography as it pertains to the study of DHF and compensated SHF in diabetes is given below.

There are two components to diastolic function: Active and passive. Whereas the active phase involves energy-dependent relaxation, the passive phase predominantly reflects the viscoelastic properties of the heart. The conventional technique for the assessment of these functions involves the interrogation of transmitral flow during diastole using Doppler echocardiography. This first focuses on the early diastolic flow that occurs when the mitral valve opens (E wave), that serves as an index of left ventricular relaxation, compliance, and atrial pressure. The E wave then is followed by the A wave of atrial contraction that heralds the end of diastole. With early diastolic dysfunction, left ventricular relaxation is slowed and the amplitude of the E wave is diminished while the contribution of atrial contraction is increased, together resulting in a reduced E:A ratio (Figure 4). However, with advancing disease, left atrial and ventricular pressure both rise, increasing the magnitude of the E wave, giving a normal E:A ratio (pseudonormal pattern) that can be unmasked by the Valsalva maneuver. With even further progression, abnormal left ventricular compliance in addition to impaired relaxation gives rise to a restrictive pattern (E:A >2). Using criteria based on these measurements, including the use of the Valsalva maneuver (64), two studies of normotensive men with well-controlled type 2 diabetes found evidence of diastolic dysfunction in 47 and 60% of patients (65,66). Furthermore, although diastolic dysfunction also is a common finding in patients with chronic kidney disease (CKD), patients with diabetic nephropathy have an even greater degree of impairment than is present in nondiabetic kidney disease (67) (Figure 5).

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

In mild diastolic dysfunction, slowed ventricular relaxation reduces the velocity of early diastolic filling (E wave) and an increase in flow velocity, with atrial contraction leading to a reduced E:A ratio. With more advanced disease, the left atrial and transmitral pressure rise, giving an E:A ratio that is similar to normal individuals (pseudonormal pattern) and that can be unmasked by the Valsalva maneuver. With further progression, left ventricular compliance is increased and a restrictive pattern is seen (156).

Figure 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5.

Percentage of patients with diastolic dysfunction according to the presence or absence of chronic renal failure (CRF) and diabetes (67).

Tissue Doppler Imaging

Although useful, a major caveat, particularly in the setting of renal disease, is the dependence of conventional echocardiographic measurements of transmitral flow on preload (volume status). Accordingly, more recent studies have used tissue Doppler imaging to provide load-independent assessments of cardiac relaxation. These include the myocardial relaxation velocity during early diastole (E′ or EM), a measurement that is frequently expressed in relation to peak early diastolic transmitral flow (E) as the E/E′ ratio to provide a more preload independent index of left ventricular filling pressure. These studies not only have confirmed evidence of diastolic dysfunction in asymptomatic patients with diabetes but also have shown a direct relationship between the extent of diastolic dysfunction and glycemic control (68) (Figure 6). Consistent with this, studies that have examined the effects of improved metabolic control with pancreas transplantation noted reversal of diastolic abnormalities in recipients of a combined kidney-pancreas transplant over a 4-yr period but not in patients with kidney transplantation alone (69).

Figure 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 6.

Relationship between glycosylated hemoglobin (HgbA1c) and left ventricular diastolic function in patients with type 1 diabetes and without overt HF (r = 0.68, P < 0.0002) (68).

Compensated Systolic Dysfunction

In addition to being able to assess diastolic relaxation, tissue Doppler is useful in the examination of cardiac contraction in systole. In particular, this technique is able to differentiate radial systolic function, as a result mainly of contraction of circumferential fibers, from the longitudinal motion that occurs as a consequence of contraction of longitudinal fibers in the subendocardium (70), a region that seems especially vulnerable to ischemic injury and fibrotic repair (71). Indeed, a number of recent studies have shown that subclinical left ventricular systolic dysfunction is a common finding in diabetes, reporting a reduction in longitudinal contraction that is compensated for by increased radial contraction so that global function is preserved (72–74). These findings suggest that both disordered diastolic and systolic function, although mostly asymptomatic, occur early in the course of diabetes.

Brain Natriuretic Peptide in Screening for Left Ventricular Dysfunction in Diabetes

There is considerable controversy regarding the clinical utility of brain natriuretic peptide (BNP) in identifying patients with asymptomatic cardiac disease among patients with diabetes. BNP is a 39–amino acid peptide that is released predominantly by the ventricle in response to intracardiac pressure and stretch. As such, it is a highly sensitive and reasonably specific marker of left ventricular systolic (and to a lesser extent diastolic) dysfunction. Accordingly, in patients with overt symptomatic HF (either diastolic or systolic), BNP is markedly elevated (75).

The role of BNP measurements in the diagnosis, prognosis, and assessment of response to therapy in HF has been the subject of intensive investigation, with recent consensus statements and critical reviews providing useful guidelines (76–78). It is in the first of these roles (diagnosis) where BNP has been evaluated the most extensively. BNP has been found to be of high sensitivity and moderate specificity (i.e., high negative predictive value) in diagnosing HF among patients with undifferentiated dyspnea in the emergency department, outpatient, and general practice settings (79,80), although potential confounders include acute conditions such as coronary syndromes and pulmonary embolism (81).

As diabetes is a known and independent risk factor for the development of HF, it has been proposed that BNP could be used to screen for and aid in the detection of subclinical left ventricular dysfunction in such patients. However, findings using this approach have been somewhat conflicting. For instance, some groups have noted that BNP can reliably screen patients with diabetes for the presence or absence of left ventricular dysfunction even in the absence of clear indications for echocardiography such as symptoms (82,83). However, a number of other groups have suggested that BNP is not capable of identifying mild left ventricular diastolic dysfunction in asymptomatic patients with diabetes, particularly when these patients do not have evidence of macrovascular disease (84,85). Moreover, kidney disease per se, in the absence of either diabetes or HF, results in elevated BNP, adding further difficulties in the interpretation of these clinical studies.

Treatment

Consistent with the common pathologic features of diabetic kidney disease and HF, the treatment of these two complications is also similar. However, whereas there is substantial information regarding the treatment and prevention of SHF in diabetes, there is a dearth of trial data in DHF.

Glycemic Control

Good glycemic control reduces the development and progression of nephropathy in type 1 and type 2 diabetes (16,86–88). Although neither the Diabetes Control and Complications Trial (DCCT) in type 1 diabetes nor the UKPDS in type 2 diabetes showed a reduction in cardiovascular events with intensive glycemic control (16,86), a prospective, observational component of UKPDS revealed a continuous relationship between glycemic exposure and the development of HF with no threshold of risk, such that for each 1% (absolute) reduction in glycosylated hemoglobin (HbA1c), there was an associated 16% decrease in hospitalization for HF (Figure 7) (89). Similar findings also were reported recently in a large cohort study from the US (90).

Figure 7.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 7.

Relative risk of HF in relation to HgbA1c in UK Prospective Diabetes Study (89).

Despite the absence of definitive interventional studies, these studies suggest that attaining optimal glycemic control should be a goal in both the treatment and the prevention of HF in patients with diabetes. However, the choice of oral hypoglycemic agent that may be used is restricted. For instance, metformin is contraindicated in the presence of either renal impairment or HF, and precautions also apply to the use of the thiazolidinediones (TZD).

TZD

The TZD are agonists of the peroxisome proliferator–activated receptor-γ (PPAR-γ), a nuclear receptor that modulates transcription of genes that are related not only to glucose and lipid metabolism but also to adipogenesis and inflammatory signaling (91). In addition to their ability to lower blood glucose by increasing insulin sensitivity, a number of rodent and small clinical studies have shown a beneficial effect of PPAR-γ agonists in diabetic nephropathy (92,93). Similarly, studies of TZD in animals and small human studies using surrogate markers of cardiovascular injury have reported beneficial effects, with larger phase III studies, assessing the effects of TZD on the progression of atherosclerosis, as measured by intravascular ultrasound (APPROACH: Rosiglitazone versus a Sulfonurea on Progression of Atherosclerosis in Patients with Cardiovascular Disease and Type 2 Diabetes, and PERISCOPE: Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation), currently in progress.

Among their multiple effects, TZD also induce fluid retention by mechanisms that are incompletely understood but include the regulation of renal sodium transport (94). Accordingly, patients with New York Heart Association (NYHA) class III or IV HF were not included in the major clinical trials of rosiglitazone and pioglitazone, so these drugs are not recommended in such patients. Although the expansion of ECFV is usually well tolerated, patients with known cardiovascular disease seem to be at increased risk for developing HF with TZD use. For instance, in patients with acute MI, TZD were associated with an increased likelihood of hospital readmission, predominately as a result of HF (95). More recently, in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events), in which patients with diabetes and known macrovascular disease were randomly assigned to receive either pioglitazone or placebo and followed for a mean of 35 mo, has been reported (96). As pointed out in the accompanying editorial (97), although pioglitazone reduced the composite of all-cause mortality, nonfatal MI, and stroke by approximately 16%, its use was associated with an increase in HF that was two-fold greater than the reduction in incidence of cardiovascular events.

In the setting of diabetic nephropathy, in which many patients likely will have asymptomatic diastolic dysfunction, an increase in ECFV potentially may precipitate pulmonary edema as a consequence of the steep pressure–volume relationship that characterizes diastolic disease. TZD, if used in such patients, should be administered with caution, commencing with low doses, careful observation, and slow, cautious dose escalation (98).

BP

The UKPDS examined the effect of BP control on the development of HF in patients with type 2 diabetes in the community setting. “Tight” BP control (achieved BP 144/82 mmHg) was associated with a 56% reduction in the risk for HF compared with less tight control (achieved BP 154/87 mmHg; P = 0.004) (17). The UKPDS further noted a significant association between HF and systolic BP (SBP), such that a 10-mmHg decrease in SBP was accompanied by a 12% decrease in HF, with no apparent threshold of risk (99). More recently, the relationship between achieved BP and cardiovascular outcomes in patients with diabetic nephropathy was examined in IDNT. This post hoc analysis showed that the effects of achieved BP were independent of treatment assignment (irbesartan, amlodipine, and placebo) (100) and that as in UKPDS, SBP and HF hospitalization were directly related such that achieving a 20-mmHg lower SBP was associated with a 25% reduction in HF events (100) (Figure 8).

Figure 8.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 8.

Relative risk of HF in relation to achieved BP in the Irbesartan Diabetic Nephropathy Trial (100).

ACE Inhibition and ARB

A large body of clinical trial data provides important evidence for the routine use of ACE inhibitors and ARB in the treatment of both diabetic nephropathy and HF. Accordingly, more recent trials have examined the use of such treatment in the prevention of HF as well as the effects of combination of ACE inhibitor and ARB with each other or with mineralocorticoid receptor blockade. Both the IDNT and RENAAL trial reported a reduction in hospitalization for new-onset HF in patients who had overt nephropathy and had received ARB therapy (31,32), apparently independent of their effects on BP (31).

Combined ACE Inhibitor and ARB

Although effective, the response to treatment with an ACE inhibitor or an ARB is incomplete, leading to the speculation that a more complete blockade of the renin-angiotensin-aldosterone system (RAAS), by synergistically combining the two classes of drugs, may be more effective than either when used as a single-agent therapy. This hypothesis is fueled by the concept of “RAAS escape.” According to this hypothesis for which some supportive data exist, constant treatment with an ACE inhibitor or an ARB eventually leads to the return of angiotensin II and aldosterone to their pretreatment levels and limiting of their long-term efficacy (101). The corollary is that dual blockade with an ACE inhibitor and an ARB should limit the reactive activation of the RAAS that results from single-agent treatment. To date, a number of studies of such dual therapy have been conducted in kidney disease. The largest study, the Combination Treatment of Angiotensin II Receptor Blocker and Angiotensin Converting Enzyme Inhibitor in nondiabetic renal disease (COOPERATE), found a beneficial effect of the combination in patients with nondiabetic kidney disease independent of any change in BP (102). Studies in diabetic nephropathy have shown reductions in proteinuria with combination therapy that have been associated with and without BP-lowering effects (103,104). Most recently, the Candesartan and Lisinopril Microalbuminuria II (CALM II), a follow-up to the first study to examine combination therapy in diabetic nephropathy, compared double-dose ACE inhibitor (lisinopril 40 mg) with dual therapy (lisinopril 20 mg with candesartan 16 mg), reporting similar reductions in BP and albuminuria with both treatment regimens (105). Thus, in diabetic nephropathy, in the absence of a definitive study with a renal function outcome, the renoprotective effects of combination therapy, beyond higher dose single-agent treatment or BP reduction, remains highly controversial.

Combination ACE Inhibitor and ARB for HF

Two major studies have explored the utility of combining ACE inhibitor with ARB in patients with HF, the CHARM-Added study (106) and the Val-HeFT (107) study. In CHARM-Added, 2548 patients who had symptomatic HF and a LVEF <40% and were treated with ACE inhibitors were assigned to 32 mg of candesartan or placebo. The primary outcome variable of cardiovascular death and HF hospitalization was met with a hazard ratio of 0.85 favoring candesartan. Although various subgroups were analyzed in the primary results manuscript, no subgroup analysis has been published yet according to presence or absence of background diabetes, which comprised 30% of the study population.

In the Val-HeFT study, patients with symptomatic HF and LVEF <40% and left ventricular internal diastolic diameter >2.9 cm/m2 were randomly assigned to valsartan (uptitrated to 320 mg/d) or placebo. Overall, the co-primary end point of mortality was not met in this study. However, the second co-primary end point of mortality and morbidity (defined as incidence of cardiac arrest and resuscitation, hospitalization for HF, or receipt of intravenous inotropic or vasodilator therapy for at least 4 h) was met with a 13.2% risk reduction with valsartan (relative risk 0.87; P = 0.009). Subgroup analysis according to presence or absence of diabetes was reported in the primary manuscript. Overall, approximately 25% of patients had diabetes in this study. There was no heterogeneity in response according to presence or absence of diabetes at baseline. However, there was a trend for less benefit (although not significantly) in patients who had diabetes at baseline.

Mineralocorticoid Receptor Antagonism

Beyond the actions of angiotensin II as the effector molecule of the RAAS, there is increasing evidence that aldosterone also contributes to heart and kidney disease (108). In the Randomized Aldactone Evaluation Study (RALES) of patients with NYHA class III to IV HF, treatment with the nonselective mineralocorticoid receptor antagonist spironolactone led to a 30% reduction in mortality at 2 yr (109). Furthermore, in patients with proteinuric renal disease in general (110) and early diabetic nephropathy in particular, spironolactone was shown to reduce proteinuria (111). However, spironolactone is a nonspecific mineralocorticoid receptor antagonist with unwanted affects on gonadal steroid receptors leading to gynecomastia as a frequent adverse effect. In contrast, eplerenone, a specific mineralocorticoid receptor antagonist, recently approved by the Food and Drug Administration, does not cause gynecomastia. In the Eplerenone Post Acute Myocardial Infraction Heart Failure Efficacy and Survival Study (EPHESUS), eplerenone reduced mortality with no heterogeneity in effect between subgroups with and without diabetes (110). Moreover, the effects of eplerenone in combination with ACE inhibition have also been examined in patients with early diabetic nephropathy, and although only published in abstract form, these studies showed a greater reduction in albumin:creatinine ratio in patients who were treated with the combination of eplerenone and enalapril than those who were treated with either drug as monotherapy (112) (Figure 9). Hyperkalemia, however, led to withdrawal from the study in 14 (21%) patients who received combination therapy, compared with six (8%) patients in the eplerenone group and 2 (3%) in those who were treated with enalapril (108,112). Whether the risk for hyperkalemia can be managed by careful patient selection, dietary potassium restriction, kaliuretic agents, and even ion exchange resins in a manner that might permit the wider use as dual cardiorenoprotective therapies remains to be determined.

Figure 9.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 9.

Percentage change in urinary albumin:creatinine ratio at week 24 in patients who were treated with eplerenone, enalapril, or their combination. P < 0.001 versus baseline (108,112).

β-Blockers

As in other groups, β-blockers also exert substantial cardioprotective effects in patients with diabetes and with kidney disease. For instance, in a meta-analysis of HF trials in which β-blockers were added to an ACE inhibitor or an ARB, patients with diabetes derived a clear beneficial effect (113). Similarly, β-blocker use in long-term dialysis patients improved survival in patients with dilated cardiomyopathy (114) and also reduced risk for new-onset HF in patients without pre-existing HF (115). However, despite compelling data in HF and ischemic heart disease, β-blockers have traditionally been avoided in patients with diabetes because of adverse effects that include hypoglycemic awareness, increased insulin resistance, dyslipidemia, and exacerbation of peripheral arterial disease. However, such risks, which mostly can be managed, need to be balanced against the significant reductions in morbidity and mortality afforded by these drugs. Indeed, the risks of hypoglycemia with β-blockers is no greater than with ACE inhibitors (116), and the newer vasodilatory β-blockers such as carvedilol, which inhibit not only β1 but also β2 and α1 receptors, seem not to have the adverse metabolic effects that beset conventional β-blockers (116) and may even reduce the likelihood of new-onset diabetes (117).

Anemia

Anemia, HF, and CKD are linked components in a vicious circle of chronic disease whereby HF leads to CKD and anemia, CKD leads to anemia and CHD, and anemia leads to HF and CKD (118). Whereas each disorder is associated with increased mortality, their combination further exacerbates risk, suggesting that optimal therapy in each condition should include treatment for all three (118).

In addition to being a common feature of CKD that parallels falling GFR, the prevalence of anemia (Hb <12 g/dl) increases with the severity of HF, reaching 79% in those with NYHA class IV disease (119). Patients with diabetes and impaired renal function may be particularly prone to anemia such that 35 to 55% of patients with diabetes and creatine clearance was <60 ml/min per 1.73 m2 are anemic (120). Indeed, for any level of renal dysfunction, diabetic subjects have lower Hb levels than their nondiabetic counterparts.

A number of small studies have examined the effects of anemia correction with erythropoietin (EPO), reporting improvements in renal and cardiac parameters (122). In a study of 179 patients with resistant HF and mild to moderate chronic kidney failure, half of whom had diabetes, the effects of correcting mild anemia (Hb 9.5 to 11.5 g/dl) with EPO and iron were examined. Among patients with diabetes, Epo-Fe treatment was associated with a mean 2.7-g/dl increase in Hb, 35% improvement in NYHA functional class, 7.4% improvement in LVEF, and a 96% reduction in the number of hospitalizations along with stabilization in the previously declining renal function (123). A large prospective study, the Anemia Correction in Diabetes (ACORD) study, is also under way to examine the use of subcutaneous epoietin-β in patients with diabetic nephropathy, comparing early treatment with a target Hb of 13 to 15 g/dl to a conventional target of 10.5 to 11.5 g/dl, with therapy initiated once Hb has fallen to <10.5 g/dl (124).

DHF and Diabetes

To date, almost all large-scale clinical trials in HF have examined patients with systolic dysfunction. However, with the realization of the contribution of HF with preserved systolic function to HF hospitalizations, recent trials have begun to explore treatment in this important group. In the CHARM-Preserved (125) study, 3023 patients with symptomatic HF and LVEF >40% were randomly assigned to candesartan (target 32 mg once daily) or placebo. There was no significant difference in the primary end point of time to cardiovascular death or hospital admission for HF between the two groups or a significant difference in mortality. Although roughly 28% of patients had diabetes in that study, there as yet has been no publication of results according to the presence or absence of diabetes in this population.

The SENIORS (126) study examined the β-blocker/vasodilator nebivolol in 2128 elderly patients with both SHF and DHF. In this study, the overall group was examined according to the presence or absence of baseline diabetes. Diabetes was present in approximately 26% of patients. Although there was no heterogeneity in the response according to presence of baseline diabetes, patients with diabetes did not seem to derive benefit from nebivolol. These analyses have not been subdivided further according to patients with SHF versus DHF as their primary condition.

The Digoxin Intervention Group (DIG) study (127) examined digoxin versus placebo in patients with predominantly SHF, although a small group of patients did have preserved systolic ventricular function (LVEF >45%). In that group, there seemed to be a similar response to digoxin to those with impaired systolic function, i.e., reduced hospitalizations and pump failure death offset by an increase in sudden death. None of these differences was statistically significant between digoxin and placebo. Diabetic responses within the preserved systolic function group have not been reported.

New Therapies

In addition to currently marketed treatments, a range of novel therapies are undergoing clinical development for the prevention and treatment of diabetic complications. As might be expected from the common pathology of diabetic nephropathy and cardiomyopathy, these new strategies have the potential to provide new therapeutic options in the management of both kidney disease and HF in diabetes. Among the most advanced in clinical development are agents that modulate advanced glycation end products (AGE) and the activity of protein kinase C (PKC).

AGE

AGE formation results from a series of nonenzymatic reactions in which sugar derivatives covalently bind to proteins, forming irreversible cross-links that may accumulate in long-lived proteins such as collagen. The quantity of AGE increases as a function of time and glucose concentration (128) such that their abundance increases in diabetes and with age. The accumulation of AGE within tissues leads to alterations in structure and function, with experimental evidence implicating them in the pathogenesis of diabetic complications, including those of the kidney and the heart. As a consequence, strategies to attenuate the pathogenetic influence of AGE include prevention of AGE formation, blockade of AGE receptors, and breakers of AGE–protein cross-links.

In experimental animal models of diabetic kidney and cardiovascular disease, blockade of AGE formation with agents such as aminoguanidine (pimagedine) results in attenuation of the disordered structure and function that develops as a consequence of aging and/or diabetes (129–131). Two clinical trials of aminoguanidine have been conducted, both in patients with diabetic nephropathy. In the aminoguanidine in overt type 1 diabetic nephropathy trial (ACTION I), which included 690 patients with type 1 diabetes, nephropathy, and retinopathy, the treated group showed a nonsignificant reduction in the primary end point of time to doubling serum creatinine, although significant reductions in secondary outcomes measures such as proteinuria and progression of retinopathy were noted (132). At the higher of the two doses used in ACTION I (150 mg twice daily and 300 mg twice daily), three study patients developed antineutrophil cytoplasmic antibody–positive crescentic glomerulonephritis, two of whom developed ESRD (132). ACTION II, a 599-patient trial in patients with type 2 diabetes, was stopped prematurely on the recommendation of the data and safety monitoring board because of adverse events (133).

In an attempt to avoid the potential toxicity of aminoguanidine, a number of other inhibitors of AGE formation have been synthesized and are undergoing preclinical and early-phase clinical evaluation. Strategies to block AGE receptor–mediated effects are also in clinical development. However, trials using compounds that can break the covalent AGE cross-links, with their potential to reverse established disease, seem to be the most advanced. These agents that include alagebrium chloride (ALT 711; Alteon Inc., Parsippany, NJ), a stable derivative of N-phenacylthiazolium bromide (134), is under investigation for a range of potential indications that include DHF and diabetic nephropathy. Indeed, the findings of a small 23-patient DHF study were published recently showing that after 16 wk, alagebrium reduced left ventricular mass along with a trend to improvement in E/E′ (135).

PKC

PKC is a ubiquitously expressed, large family of serine-threonine kinases that transduce a wide range of cell-signaling processes by catalyzing substrate-specific phosphorylation. Those of particular relevance to cardiac and renal disease include PKC-mediated increases in TGF-β and matrix-protein expression, activation of mitogen-activated protein kinase, and phenotypic changes in endothelial and smooth muscle cells. At present, there are several PKC inhibitors in preclinical and clinical development that differ in their specificity and mechanisms of action (136). To date, the PKC inhibitor that has been studied most extensively in renal disease is ruboxistaurin (LY 333531; Eli-Lilly and Co., Indianapolis, IN), a specific inhibitor of the PKC-β isoform (137). In studies in diabetic rodents, ruboxistaurin was shown not only to reduce TGF-β and collagen expression (138) but also to attenuate mesangial expansion (139) and albuminuria (137) with evidence of renoprotection despite the presence of continuing hyperglycemia and hypertension (140,141).

In a recently reported pilot phase 2 clinical study, patients with type 2 diabetes and nephropathy were administered ruboxistaurin 32 mg/d along with continued ACE inhibitor and/or ARB for 12 mo, noting a significant decrease in albumin:creatinine ratio from baseline of 24% (P = 0.02) that did not change in the placebo group (−9%; P = 0.33) (142). Furthermore, estimated GFR fell over 1 yr in placebo-treated patients (modified Modification of Diet in Renal Disease −4.8 ± 1.8 ml/min per yr; P = 0.009) but not in the ruboxistaurin-treated group (−2.5 ± 1.9 ml/min per yr; P = 0.185).

In addition to its effects in the kidney, a number of preclinical and human studies suggest a role for PKC-β in the pathogenesis of HF. For instance, PKC-β expression is significantly increased in the failing human heart (143), and mice that overexpress PKC-β in their myocardium exhibit changes similar to those of diabetic cardiomyopathy with left ventricular hypertrophy, myocyte necrosis, cardiac fibrosis, and decreased left ventricular function (144). Moreover, treating rats with ruboxistaurin after MI reduces both cardiac fibrosis and the progressive decline in cardiac function (71). However, although encouraging, to date, the effects of ruboxistaurin in humans with HF have not been examined.

Antifibrotic Therapies

Myocardial fibrosis is a key feature of both diabetic cardiomyopathy and nephropathy. In the heart, fibrosis leads to reduced myocardial elasticity, impaired contractility, and overt cardiac dysfunction (65,66,145,146), and in the kidney, the extent of both glomerulosclerosis and tubulointerstitial fibrosis are closely related to declining renal function (147,148). Accordingly, strategies that reduce the pathologic accumulation of extracellular matrix have been advocated as potential therapies for the treatment and prevention of HF and kidney failure in both diabetic and nondiabetic states. Among potential therapies is tranilast (n-[3,4-dimethoxycinnamoyl] anthranilic acid), an antifibrotic compound that is used in Japan for the treatment of hypertrophic scars (149) and also has been shown to reduce cardiac (150,151) and renal pathology (152,153) in experimental studies, with a pilot clinical trial suggesting a beneficial effect on the progression of renal dysfunction in patients with diabetic nephropathy when added to an ACE inhibitor or an ARB (154).

Conclusion

HF is an important comorbidity in patients with diabetic nephropathy, with common pathogenetic processes underlying both disorders. Although agents that block the RAAS are routinely used in managing chronic kidney and heart disease, β-blockers remain underused, despite their proven benefit in patients with diabetes and HF. In the same way that microalbuminuria is used as an early indicator of nephropathy, it is possible that in the future, sensitive echocardiographic or other noninvasive measurements might become more widely available for the diagnosis of preclinical cardiac dysfunction in diabetes. Such measurements may pave the way for studies that examine new therapies that prevent the progression of both kidney and cardiac dysfunction in diabetes.

Acknowledgments

Support for this review was provided by Research Grants from the Juvenile Diabetes Research Foundation and the National Health and Medical Research Council of Australia.

We regret that because of space constraints, we were not able to cite the excellent work of many investigators in the field.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • Copyright © 2006 by the American Society of Nephrology

References

  1. ↵
    Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047–1053, 2004
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Krum H, Gilbert RE: Demographics and concomitant disorders in heart failure. Lancet 362: 147–158, 2003
    OpenUrlCrossRefPubMed
  3. ↵
    Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286: 421–426, 2001
    OpenUrlCrossRefPubMed
  4. ↵
    Rich MW: Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Geriatr Soc 45: 968–974, 1997
    OpenUrlCrossRefPubMed
  5. ↵
    Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D’Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJ, Levy D: Lifetime risk for developing congestive heart failure: The Framingham Heart Study. Circulation 106: 3068–3072, 2002
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS: Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347: 1397–1402, 2002
    OpenUrlCrossRefPubMed
  7. ↵
    Young JB: The global epidemiology of heart failure. Med Clin North Am 88: 1135–114 3, ix, 2004
    OpenUrlCrossRefPubMed
  8. ↵
    American Heart Association: Congestive heart failure. Heart Disease and Stroke Statistics, 2005 Update: 26–27, 2005. Available online at www.americanheart.org
  9. ↵
    McKee PA, Castelli WP, McNamara PM, Kannel WB: The natural history of congestive heart failure: The Framingham study. N Engl J Med 285: 1441–1446, 1971
    OpenUrlCrossRefPubMed
  10. ↵
    Kannel WB, Hjortland M, Castelli WP: Role of diabetes in congestive heart failure: The Framingham study. Am J Cardiol 34: 29–34, 1974
    OpenUrlCrossRefPubMed
  11. ↵
    Chen YT, Vaccarino V, Williams CS, Butler J, Berkman LF, Krumholz HM: Risk factors for heart failure in the elderly: A prospective community-based study. Am J Med 106: 605–612, 1999
    OpenUrlCrossRefPubMed
  12. Chae CU, Pfeffer MA, Glynn RJ, Mitchell GF, Taylor JO, Hennekens CH: Increased pulse pressure and risk of heart failure in the elderly. JAMA 281: 634–639, 1999
    OpenUrlCrossRefPubMed
  13. ↵
    He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK: Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 161: 996–1002, 2001
    OpenUrlCrossRefPubMed
  14. ↵
    Nichols GA, Hillier TA, Erbey JR, Brown JB: Congestive heart failure in type 2 diabetes: Prevalence, incidence, and risk factors. Diabetes Care 24: 1614–1619, 2001
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Bell DS: Heart failure: The frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 26: 2433–2441, 2003
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Group U: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–853, 1998
    OpenUrlCrossRefPubMed
  17. ↵
    UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317: 703–713, 1998
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Chae CU, Albert CM, Glynn RJ, Guralnik JM, Curhan GC: Mild renal insufficiency and risk of congestive heart failure in men and women > or =70 years of age. Am J Cardiol 92: 682–686, 2003
    OpenUrlCrossRefPubMed
  19. ↵
    Fried LF, Shlipak MG, Crump C, Bleyer AJ, Gottdiener JS, Kronmal RA, Kuller LH, Newman AB: Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 41: 1364–1372, 2003
    OpenUrlCrossRefPubMed
  20. ↵
    Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32: S112–119, 1998
    OpenUrlCrossRefPubMed
  21. ↵
    Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS: Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors. Kidney Int 47: 884–890, 1995
    OpenUrlCrossRefPubMed
  22. ↵
    Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW: The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 35: 681–689, 2000
    OpenUrlCrossRefPubMed
  23. ↵
    Jarrett RJ, Viberti GC, Argyropoulos A, Hill RD, Mahmud U, Murrells TJ: Microalbuminuria predicts mortality in non-insulin-dependent diabetics. Diabet Med 1: 17–19, 1984
    OpenUrlCrossRefPubMed
  24. Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310: 356–360, 1984
    OpenUrlCrossRefPubMed
  25. Borch-Johnsen K, Kreiner S: Proteinuria: Value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. BMJ (Clin Res Ed) 294: 1651–1654, 1987
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Mattock MB, Barnes DJ, Viberti G, Keen H, Burt D, Hughes JM, Fitzgerald AP, Sandhu B, Jackson PG: Microalbuminuria and coronary heart disease in NIDDM: An incidence study. Diabetes 47: 1786–1792, 1998
    OpenUrlAbstract
  27. ↵
    Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342: 145–153, 2000
    OpenUrlCrossRefPubMed
  28. ↵
    Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 355: 253–259, 2000
    OpenUrlCrossRefPubMed
  29. ↵
    Vaur L, Gueret P, Lievre M, Chabaud S, Passa P: Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: Observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study. Diabetes Care 26: 855–860, 2003
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851–860, 2001
    OpenUrlCrossRefPubMed
  31. ↵
    Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ: Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 138: 542–549, 2003
    OpenUrlCrossRefPubMed
  32. ↵
    Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861–869, 2001
    OpenUrlCrossRefPubMed
  33. ↵
    Wang SL, Head J, Stevens L, Fuller JH: Excess mortality and its relation to hypertension and proteinuria in diabetic patients. The World Health Organization multinational study of vascular disease in diabetes. Diabetes Care 19: 305–312, 1996
    OpenUrlAbstract/FREE Full Text
  34. ↵
    de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110: 921–927, 2004
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Remuzzi G, Ruggenenti P, Perna A, Dimitrov BD, de Zeeuw D, Hille DA, Shahinfar S, Carides GW, Brenner BM: Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: A post hoc analysis of the RENAAL trial results. J Am Soc Nephrol 15: 3117–3125, 2004
    OpenUrlAbstract/FREE Full Text
  36. ↵
    Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr, Sowers JR: Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation 100: 1134–1146, 1999
    OpenUrlFREE Full Text
  37. ↵
    Abaci A, Oguzhan A, Kahraman S, Eryol NK, Unal S, Arinc H, Ergin A: Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 99: 2239–2242, 1999
    OpenUrlAbstract/FREE Full Text
  38. ↵
    Chou E, Suzuma I, Way KJ, Opland D, Clermont AC, Naruse K, Suzuma K, Bowling NL, Vlahos CJ, Aiello LP, King GL: Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: A possible explanation for impaired collateral formation in cardiac tissue. Circulation 105: 373–379, 2002
    OpenUrlAbstract/FREE Full Text
  39. ↵
    Waltenberger J: Impaired collateral vessel development in diabetes: Potential cellular mechanisms and therapeutic implications. Cardiovasc Res 49: 554–560, 2001
    OpenUrlCrossRefPubMed
  40. ↵
    Mak KH, Moliterno DJ, Granger CB, Miller DP, White HD, Wilcox RG, Califf RM, Topol EJ: Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 30: 171–179, 1997
    OpenUrlCrossRefPubMed
  41. ↵
    Zuanetti G, Latini R, Maggioni AP, Santoro L, Franzosi MG: Influence of diabetes on mortality in acute myocardial infarction: Data from the GISSI-2 study. J Am Coll Cardiol 22: 1788–1794, 1993
    OpenUrlCrossRefPubMed
  42. ↵
    Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: The Bypass Angioplasty Revascularization Investigation (BARI). Circulation 96: 1761–1769, 1997
    OpenUrlAbstract/FREE Full Text
  43. ↵
    Weintraub WS, Stein B, Kosinski A, Douglas JS Jr, Ghazzal ZM, Jones EL, Morris DC, Guyton RA, Craver JM, King SB 3rd: Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease. J Am Coll Cardiol 31: 10–19, 1998
    OpenUrlCrossRefPubMed
  44. ↵
    Herlitz J, Wognsen GB, Emanuelsson H, Haglid M, Karlson BW, Karlsson T, Albertsson P, Westberg S: Mortality and morbidity in diabetic and nondiabetic patients during a 2-year period after coronary artery bypass grafting. Diabetes Care 19: 698–703, 1996
    OpenUrlAbstract/FREE Full Text
  45. ↵
    Barsness GW, Peterson ED, Ohman EM, Nelson CL, DeLong ER, Reves JG, Smith PK, Anderson RD, Jones RH, Mark DB, Califf RM: Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation 96: 2551–2556, 1997
    OpenUrlAbstract/FREE Full Text
  46. ↵
    Stone PH, Muller JE, Hartwell T, York BJ, Rutherford JD, Parker CB, Turi ZG, Strauss HW, Willerson JT, Robertson T, et al.: The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: Contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J Am Coll Cardiol 14: 49–57, 1989
    OpenUrlCrossRefPubMed
  47. ↵
    Prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic risk factors in noninsulin-dependent diabetes mellitus. Milan Study on Atherosclerosis and Diabetes (MiSAD) Group. Am J Cardiol 79: 134–139, 1997
    OpenUrlCrossRefPubMed
  48. ↵
    Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351: 1285–1295, 2004
    OpenUrlCrossRefPubMed
  49. ↵
    Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A: New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30: 595–602, 1972
    OpenUrlCrossRefPubMed
  50. ↵
    Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, Nadal-Ginard B, Anversa P: Myocardial cell death in human diabetes. Circ Res 87: 1123–1132, 2000
    OpenUrlAbstract/FREE Full Text
  51. ↵
    Factor SM, Okun EM, Minase T: Capillary microaneurysms in the human diabetic heart. N Engl J Med 302: 384–388, 1980
    OpenUrlCrossRefPubMed
  52. ↵
    Watts GF, Marwick TH: Ventricular dysfunction in early diabetic heart disease: Detection, mechanisms and significance. Clin Sci (Lond) 105: 537–540, 2003
    OpenUrlPubMed
  53. ↵
    Fang ZY, Prins JB, Marwick TH: Diabetic cardiomyopathy: Evidence, mechanisms, and therapeutic implications. Endocr Rev 25: 543–567, 2004
    OpenUrlCrossRefPubMed
  54. Hayat SA, Patel B, Khattar RS, Malik RA: Diabetic cardiomyopathy: Mechanisms, diagnosis and treatment. Clin Sci (Lond) 107: 539–557, 2004
    OpenUrlAbstract/FREE Full Text
  55. ↵
    Taegtmeyer H, McNulty P, Young ME: Adaptation and maladaptation of the heart in diabetes: Part I: General concepts. Circulation 105: 1727–1733, 2002
    OpenUrlFREE Full Text
  56. ↵
    Marwick TH: Diabetic heart disease. Heart Sept 13, 2005 [epub ahead of print]
  57. ↵
    Tarnow L, Rossing P, Gall MA, Nielsen FS, Parving HH: Prevalence of arterial hypertension in diabetic patients before and after the Jnc-V. Diabetes Care 17: 1247–1251, 1994
    OpenUrlAbstract/FREE Full Text
  58. ↵
    van Hoeven KH, Factor SM: A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation 82: 848–855, 1990
    OpenUrlAbstract/FREE Full Text
  59. ↵
    Vasan RS, Benjamin EJ, Levy D: Prevalence, clinical features and prognosis of diastolic heart failure: An epidemiologic perspective. J Am Coll Cardiol 26: 1565–1574, 1995
    OpenUrlCrossRefPubMed
  60. ↵
    Piccini JP, Klein L, Gheorghiade M, Bonow RO: New insights into diastolic heart failure: Role of diabetes mellitus. Am J Med 116[Suppl 5A]: 64S–75S, 2004
    OpenUrlCrossRef
  61. ↵
    Vasan RS, Benjamin EJ: Diastolic heart failure—No time to relax. N Engl J Med 344: 56–59, 2001
    OpenUrlCrossRefPubMed
  62. ↵
    Vasan RS, Levy D: Defining diastolic heart failure: A call for standardized diagnostic criteria. Circulation 101: 2118–2121, 2000
    OpenUrlFREE Full Text
  63. ↵
    Garcia MJ, Thomas JD, Klein AL: New Doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol 32: 865–875, 1998
    OpenUrlCrossRefPubMed
  64. ↵
    Rakowski H, Appleton C, Chan KL, Dumesnil JG, Honos G, Jue J, Koilpillai C, Lepage S, Martin RP, Mercier LA, O’Kelly B, Prieur T, Sanfilippo A, Sasson Z, Alvarez N, Pruitt R, Thompson C, Tomlinson C: Canadian consensus recommendations for the measurement and reporting of diastolic dysfunction by echocardiography: From the Investigators of Consensus on Diastolic Dysfunction by Echocardiography. J Am Soc Echocardiogr 9: 736–760, 1996
    OpenUrlCrossRefPubMed
  65. ↵
    Zabalgoitia M, Ismaeil MF, Anderson L, Maklady FA: Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. Am J Cardiol 87: 320–323, 2001
    OpenUrlCrossRefPubMed
  66. ↵
    Poirier P, Bogaty P, Garneau C, Marois L, Dumesnil JG: Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: Importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 24: 5–10, 2001
    OpenUrlAbstract/FREE Full Text
  67. ↵
    Miyazato J, Horio T, Takiuchi S, Kamide K, Sasaki O, Nakamura S, Nakahama H, Inenaga T, Takishita S, Kawano Y: Left ventricular diastolic dysfunction in patients with chronic renal failure: Impact of diabetes mellitus. Diabet Med 22: 730–736, 2005
    OpenUrlCrossRefPubMed
  68. ↵
    Shishehbor MH, Hoogwerf BJ, Schoenhagen P, Marso SP, Sun JP, Li J, Klein AL, Thomas JD, Garcia MJ: Relation of hemoglobin A1c to left ventricular relaxation in patients with type 1 diabetes mellitus and without overt heart disease. Am J Cardiol 91: 1514–151 7, A9, 2003
    OpenUrlCrossRefPubMed
  69. ↵
    Fiorina P, La Rocca E, Astorri E, Lucignani G, Rossetti C, Fazio F, Giudici D, di Carlo V, Cristallo M, Pozza G, Secchi A: Reversal of left ventricular diastolic dysfunction after kidney-pancreas transplantation in type 1 diabetic uremic patients. Diabetes Care 23: 1804–1810, 2000
    OpenUrlAbstract/FREE Full Text
  70. ↵
    Greenbaum RA, Ho SY, Gibson DG, Becker AE, Anderson RH: Left ventricular fibre architecture in man. Br Heart J 45: 248–263, 1981
    OpenUrlAbstract/FREE Full Text
  71. ↵
    Boyle AJ, Kelly DJ, Zhang Y, Cox AJ, Gow RM, Way K, Itescu S, Krum H, Gilbert RE: Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction. J Mol Cell Cardiol 39: 213–221, 2005
    OpenUrlCrossRefPubMed
  72. ↵
    Vinereanu D, Nicolaides E, Tweddel AC, Madler CF, Holst B, Boden LE, Cinteza M, Rees AE, Fraser AG: Subclinical left ventricular dysfunction in asymptomatic patients with type II diabetes mellitus, related to serum lipids and glycated haemoglobin. Clin Sci (Lond) 105: 591–599, 2003
    OpenUrlAbstract/FREE Full Text
  73. Andersen NH, Poulsen SH, Eiskjaer H, Poulsen PL, Mogensen CE: Decreased left ventricular longitudinal contraction in normotensive and normoalbuminuric patients with type II diabetes mellitus: A Doppler tissue tracking and strain rate echocardiography study. Clin Sci (Lond) 105: 59–66, 2003
    OpenUrlCrossRefPubMed
  74. ↵
    Fang ZY, Leano R, Marwick TH: Relationship between longitudinal and radial contractility in subclinical diabetic heart disease. Clin Sci (Lond) 106: 53–60, 2004
    OpenUrlCrossRefPubMed
  75. ↵
    Maisel AS: The diagnosis of acute congestive heart failure: Role of BNP measurements. Heart Fail Rev 8: 327–334, 2003
    OpenUrlCrossRefPubMed
  76. ↵
    McCullough PA: B-type natriuretic peptide and its clinical implications in heart failure. Am Heart Hosp J 2: 26–33, 2004
    OpenUrlPubMed
  77. Silver MA, Maisel A, Yancy CW, McCullough PA, Burnett JC Jr, Francis GS, Mehra MR, Peacock WF 4th, Fonarow G, Gibler WB, Morrow DA, Hollander J: BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 10: 1–30, 2004
    OpenUrlCrossRefPubMed
  78. ↵
    Rodeheffer RJ: Measuring plasma B-type natriuretic peptide in heart failure: Good to go in 2004? J Am Coll Cardiol 44: 740–749, 2004
    OpenUrlCrossRefPubMed
  79. ↵
    Wright SP, Doughty RN, Pearl A, Gamble GD, Whalley GA, Walsh HJ, Gordon G, Bagg W, Oxenham H, Yandle T, Richards M, Sharpe N: Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: A randomized, controlled trial. J Am Coll Cardiol 42: 1793–1800, 2003
    OpenUrlCrossRefPubMed
  80. ↵
    Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347: 161–167, 2002
    OpenUrlCrossRefPubMed
  81. ↵
    Richards AM, Cohn JN: N-terminal pro-brain natriuretic peptide: A powerful biomarker of cardiac disease. J Card Fail 11: 1–2, 2005
    OpenUrlCrossRefPubMed
  82. ↵
    Magnusson M, Melander O, Israelsson B, Grubb A, Groop L, Jovinge S: Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease. Diabetes Care 27: 1929–1935, 2004
    OpenUrlAbstract/FREE Full Text
  83. ↵
    Epshteyn V, Morrison K, Krishnaswamy P, Kazanegra R, Clopton P, Mudaliar S, Edelman S, Henry R, Maisel A: Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care 26: 2081–2087, 2003
    OpenUrlAbstract/FREE Full Text
  84. ↵
    Valle R, Bagolin E, Canali C, Giovinazzo P, Barro S, Aspromonte N, Carbonieri E, Milani L: The BNP assay does not identify mild left ventricular diastolic dysfunction in asymptomatic diabetic patients. Eur J Echocardiogr May 7, 2005 [epub ahead of print]
  85. ↵
    Igarashi M, Jimbu Y, Hirata A, Tominaga M: Characterization of plasma brain natriuretic peptide level in patients with type 2 diabetes. Endocr J 52: 353–362, 2005
    OpenUrlCrossRefPubMed
  86. ↵
    Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977–986, 1993
    OpenUrlCrossRefPubMed
  87. Gilbert RE, Tsalamandris C, Bach L, Panagiotopoulos S, O’Brien RC, Allen TJ, Goodall I, Seeman E, Cooper ME, Murray R, Jerums G: Glycemic control and the rate of progression of early diabetic kidney disease. Kidney Int 44: 855–859, 1993
    OpenUrlCrossRefPubMed
  88. ↵
    Krolewski AS, Laffel LM, Krolewski M, Quinn M, Warram JH: Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 332: 1251–1255, 1995
    OpenUrlCrossRefPubMed
  89. ↵
    Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 321: 405–412, 2000
    OpenUrlAbstract/FREE Full Text
  90. ↵
    Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, Selby JV: Glycemic control and heart failure among adult patients with diabetes. Circulation 103: 2668–2673, 2001
    OpenUrlAbstract/FREE Full Text
  91. ↵
    Rosen ED, Spiegelman BM: PPARgamma: A nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276: 37731–37734, 2001
    OpenUrlFREE Full Text
  92. ↵
    Guan Y: Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. J Am Soc Nephrol 15: 2801–2815, 2004
    OpenUrlAbstract/FREE Full Text
  93. ↵
    Pistrosch F, Herbrig K, Kindel B, Passauer J, Fischer S, Gross P: Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 54: 2206–2211, 2005
    OpenUrlAbstract/FREE Full Text
  94. ↵
    Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T: Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci U S A 102: 9406–9411, 2005
    OpenUrlAbstract/FREE Full Text
  95. ↵
    Inzucchi SE, Masoudi FA, Wang Y, Kosiborod M, Foody JM, Setaro JF, Havranek EP, Krumholz HM: Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: Insights from the National Heart Care Project. Diabetes Care 28: 1680–1689, 2005
    OpenUrlAbstract/FREE Full Text
  96. ↵
    Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 366: 1279–1289, 2005
    OpenUrlCrossRefPubMed
  97. ↵
    Yki-Jarvinen H: The PROactive study: Some answers, many questions. Lancet 366: 1241–1242, 2005
    OpenUrlCrossRefPubMed
  98. ↵
    Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R: Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27: 256–263, 2004
    OpenUrlFREE Full Text
  99. ↵
    Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. BMJ 321: 412–419, 2000
    OpenUrlAbstract/FREE Full Text
  100. ↵
    Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Pohl M, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ: Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 16: 2170–2179, 2005
    OpenUrlAbstract/FREE Full Text
  101. ↵
    Lakkis J, Lu WX, Weir MR: RAAS escape: A real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr Hypertens Rep 5: 408–417, 2003
    OpenUrlCrossRefPubMed
  102. ↵
    Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 361: 117–124, 2003
    OpenUrlCrossRefPubMed
  103. ↵
    Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH: Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 63: 1874–1880, 2003
    OpenUrlCrossRefPubMed
  104. ↵
    Rossing K, Jacobsen P, Pietraszek L, Parving HH: Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: A randomized double-blind crossover trial. Diabetes Care 26: 2268–2274, 2003
    OpenUrlAbstract/FREE Full Text
  105. ↵
    Andersen NH, Poulsen PL, Knudsen ST, Poulsen SH, Eiskjaer H, Hansen KW, Helleberg K, Mogensen CE: Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: The CALM II study. Diabetes Care 28: 273–277, 2005
    OpenUrlAbstract/FREE Full Text
  106. ↵
    McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet 362: 767–771, 2003
    OpenUrlCrossRefPubMed
  107. ↵
    Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345: 1667–1675, 2001
    OpenUrlCrossRefPubMed
  108. ↵
    Hollenberg NK: Aldosterone in the development and progression of renal injury. Kidney Int 66: 1–9, 2004
    OpenUrlCrossRefPubMed
  109. ↵
    Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709–717, 1999
    OpenUrlCrossRefPubMed
  110. ↵
    Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309–1321, 2003
    OpenUrlCrossRefPubMed
  111. ↵
    Sato A, Hayashi K, Naruse M, Saruta T: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41: 64–68, 2003
    OpenUrlAbstract/FREE Full Text
  112. ↵
    Epstein M, Buckalew V, Martinez F, Atamirano J, Roniker B, Kleiman J, Krause S: Anti-proteinuric efficacy of eplerenone, enalapril and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria [Abstract]. Am J Hypertens 15: 24A, 2002
    OpenUrlCrossRef
  113. ↵
    Haas SJ, Vos T, Gilbert RE, Krum H: Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 146: 848–853, 2003
    OpenUrlCrossRefPubMed
  114. ↵
    Cice G, Ferrara L, D’Andrea A, D’Isa S, Di Benedetto A, Cittadini A, Russo PE, Golino P, Calabro R: Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: A prospective, placebo-controlled trial. J Am Coll Cardiol 41: 1438–1444, 2003
    OpenUrlCrossRefPubMed
  115. ↵
    Abbott KC, Trespalacios FC, Agodoa LY, Taylor AJ, Bakris GL: Beta-blocker use in long-term dialysis patients: Association with hospitalized heart failure and mortality. Arch Intern Med 164: 2465–2471, 2004
    OpenUrlCrossRefPubMed
  116. ↵
    Shorr RI, Ray WA, Daugherty JR, Griffin MR: Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 278: 40–43, 1997
    OpenUrlCrossRefPubMed
  117. ↵
    Fonarow GC: Managing the patient with diabetes mellitus and heart failure: Issues and considerations. Am J Med 116[Suppl 5A]: 76S–88S, 2004
    OpenUrlCrossRef
  118. ↵
    Silverberg D, Wexler D, Blum M, Wollman Y, Iaina A: The cardio-renal anaemia syndrome: Does it exist? Nephrol Dial Transplant 18[Suppl 8]: viii7–viii12, 2003
    OpenUrl
  119. ↵
    Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, Brosh D, Laniado S, Schwartz D, Yachnin T, Shapira I, Gavish D, Baruch R, Koifman B, Kaplan C, Steinbruch S, Iaina A: The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35: 1737–1744, 2000
    OpenUrlCrossRefPubMed
  120. ↵
    Thomas MC, MacIsaac RJ, Tsalamandris C, Power D, Jerums G: Unrecognized anemia in patients with diabetes: A cross-sectional survey. Diabetes Care 26: 1164–1169, 2003
    OpenUrlAbstract/FREE Full Text
  121. Ishimura E, Nishizawa Y, Okuno S, Matsumoto N, Emoto M, Inaba M, Kawagishi T, Kim CW, Morii H: Diabetes mellitus increases the severity of anemia in non-dialyzed patients with renal failure. J Nephrol 11: 83–86, 1998
    OpenUrlPubMed
  122. ↵
    McCullough PA, Lepor NE: The deadly triangle of anemia, renal insufficiency, and cardiovascular disease: Implications for prognosis and treatment. Rev Cardiovasc Med 6: 1–10, 2005
    OpenUrlCrossRefPubMed
  123. ↵
    Silverberg DS, Wexler D, Blum M, Tchebiner JZ, Sheps D, Keren G, Schwartz D, Baruch R, Yachnin T, Shaked M, Schwartz I, Steinbruch S, Iaina A: The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 18: 141–146, 2003
    OpenUrlCrossRefPubMed
  124. ↵
    Ritz E: Managing anaemia and diabetes: A future challenge for nephrologists. Nephrol Dial Transplant 20[Suppl 6]: vi21–vi25, 2005
    OpenUrl
  125. ↵
    Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 362: 777–781, 2003
    OpenUrlCrossRefPubMed
  126. ↵
    Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Bohm M, Anker SD, Thompson SG, Poole-Wilson PA: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26: 215–225, 2005
    OpenUrlCrossRefPubMed
  127. ↵
    The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 336: 525–533, 1997
    OpenUrlCrossRefPubMed
  128. ↵
    Bendayan M: Immunocytochemical detection of advanced glycated end products in rat renal tissue as a function of age and diabetes. Kidney Int 54: 438–447, 1998
    OpenUrlCrossRefPubMed
  129. ↵
    Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G: Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 40: 1328–1334, 1991
    OpenUrlAbstract/FREE Full Text
  130. Avendano GF, Agarwal RK, Bashey RI, Lyons MM, Soni BJ, Jyothirmayi GN, Regan TJ: Effects of glucose intolerance on myocardial function and collagen-linked glycation. Diabetes 48: 1443–1447, 1999
    OpenUrlAbstract
  131. ↵
    Rumble JR, Cooper ME, Soulis T, Cox A, Wu L, Youssef S, Jasik M, Jerums G, Gilbert RE: Vascular hypertrophy in experimental diabetes: Role of advanced glycation end products. J Clin Invest 99: 1016–1027, 1997
    OpenUrlCrossRefPubMed
  132. ↵
    Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, Foiles PG, Freedman BI, Raskin P, Ratner RE, Spinowitz BS, Whittier FC, Wuerth JP: Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 24: 32–40, 2004
    OpenUrlCrossRefPubMed
  133. ↵
    Freedman BI, Wuerth JP, Cartwright K, Bain RP, Dippe S, Hershon K, Mooradian AD, Spinowitz BS: Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials 20: 493–510, 1999
    OpenUrlCrossRefPubMed
  134. ↵
    Vasan S, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, Basgen J, Wagle D, Shih D, Terlecky I, Bucala R, Cerami A, Egan J, Ulrich P: An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 382: 275–278, 1996
    OpenUrlCrossRefPubMed
  135. ↵
    Little WC, Zile MR, Kitzman DW, Hundley WG, O’Brien TX, Degroof RC: The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 11: 191–195, 2005
    OpenUrlCrossRefPubMed
  136. ↵
    Gilbert RE, Kelly DJ, Atkins RC: Novel approaches to the treatment of progressive renal disease. Curr Opin Pharmacol 1: 183–189, 2001
    OpenUrlCrossRefPubMed
  137. ↵
    Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell S-E, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King GL: Amelioration of vascular dysfunction in diabetic rats by an oral PKC beta inhibitor. Science 272: 728–731, 1996
    OpenUrlAbstract/FREE Full Text
  138. ↵
    Koya D, Jirousek MR, You-Wei L, Ishii H, Kuboki K, King GL: Characterization of protein kinase C beta isoform activation on gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 100: 115–126, 1997
    OpenUrlCrossRefPubMed
  139. ↵
    Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S, Sugimoto T, Yasuda H, Kashiwagi A, Ways DK, King GL, Kikkawa R: Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 14: 439–447, 2000
    OpenUrlCrossRefPubMed
  140. ↵
    Kelly DJ, Hepper C, Zhang Y, Jaworski K, Wilkinson-Berka JL, Gilbert RE: Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 52: 512–518, 2003
    OpenUrlAbstract/FREE Full Text
  141. ↵
    Kelly DJ, Chanty A, Gow RM, Zhang Y, Gilbert RE: Protein kinase Cbeta inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy. J Am Soc Nephrol 16: 1654–1660, 2005
    OpenUrlAbstract/FREE Full Text
  142. ↵
    Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW: The effects of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care: 28: 2686–2690, 2005
    OpenUrlAbstract/FREE Full Text
  143. ↵
    Bowling N, Walsh RA, Song G, Estridge T, Sandusky GE, Fouts RL, Mintze K, Pickard T, Roden R, Bristow MR, Sabbah HN, Mizrahi JL, Gromo G, King GL, Vlahos CJ: Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. Circulation 99: 384–391, 1999
    OpenUrlAbstract/FREE Full Text
  144. ↵
    Wakasaki H, Koya D, Schoen FJ, Jirousek MR, Ways DK, Hoit BD, Walsh RA, King GL: Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. Proc Natl Acad Sci U S A 94: 9320–9325, 1997
    OpenUrlAbstract/FREE Full Text
  145. ↵
    Gustafsson I, Hildebrandt P: Early failure of the diabetic heart. Diabetes Care 24: 3–4, 2001
    OpenUrlFREE Full Text
  146. ↵
    Bell DS: Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease? Diabetes Care 18: 708–714, 1995
    OpenUrlAbstract/FREE Full Text
  147. ↵
    Mauer S, Steffes M, Ellis E, Sutherland D, Brown D, Goetz F: Structural-functional relationships in diabetic nephropathy. J Clin Invest 74: 1143–1155, 1984
    OpenUrlCrossRefPubMed
  148. ↵
    Gilbert RE, Cooper ME: The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury? Kidney Int 56: 1627–1637, 1999
    OpenUrlCrossRefPubMed
  149. ↵
    Shigeki S, Murakami T, Yata N, Ikuta Y: Treatment of keloid and hypertrophic scars by iontophoretic transdermal delivery of tranilast. Scand J Plast Reconstr Surg Hand Surg 31: 151–158, 1997
    OpenUrlCrossRefPubMed
  150. ↵
    Pinto YM, Pinto-Sietsma SJ, Philipp T, Engler S, Kobetamehl P, Hocher B, Marquardt H, Sethmann S, Lauster R, Merker HJ, Paul M: Reduction in left ventricular messenger RNA for transforming growth factor beta(1) attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR(mRen2)27 rat. Hypertension 36: 747–754, 2000
    OpenUrlAbstract/FREE Full Text
  151. ↵
    Martin J, Kelly DJ, Mifsud SA, Zhang Y, Cox AJ, See F, Krum H, Wilkinson-Berka J, Gilbert RE: Tranilast attenuates cardiac matrix deposition in experimental diabetes: Role of transforming growth factor-beta. Cardiovasc Res 65: 694–701, 2005
    OpenUrlCrossRefPubMed
  152. ↵
    Mifsud S, Kelly DJ, Qi W, Zhang Y, Pollock CA, Wilkinson-Berka JL, Gilbert RE: Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy. Nephron Physiol 95: 83–91, 2003
    OpenUrlCrossRef
  153. ↵
    Kelly DJ, Zhang Y, Gow R, Gilbert RE: Tranilast attenuates structural and functional aspects of renal injury in the remnant kidney model. J Am Soc Nephrol 15: 2619–2629, 2004
    OpenUrlAbstract/FREE Full Text
  154. ↵
    Soma J, Sugawara T, Huang YD, Nakajima J, Kawamura M: Tranilast slows the progression of advanced diabetic nephropathy. Nephron 92: 693–698, 2002
    OpenUrlCrossRefPubMed
  155. ↵
    USRDS: 2004 USRDS Annual Data Report: Cardiovascular Special Studies. 2004, pp 167–178. Available: http://www.usrds.org
  156. ↵
    Aurigemma GP, Gaasch WH: Clinical practice. Diastolic heart failure. N Engl J Med 351: 1097–1105, 2004
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology
Vol. 1, Issue 2
March 2006
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Heart Failure and Nephropathy: Catastrophic and Interrelated Complications of Diabetes
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Heart Failure and Nephropathy: Catastrophic and Interrelated Complications of Diabetes
Richard E. Gilbert, Kim Connelly, Darren J. Kelly, Carol A. Pollock, Henry Krum
CJASN Mar 2006, 1 (2) 193-208; DOI: 10.2215/CJN.00540705

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Heart Failure and Nephropathy: Catastrophic and Interrelated Complications of Diabetes
Richard E. Gilbert, Kim Connelly, Darren J. Kelly, Carol A. Pollock, Henry Krum
CJASN Mar 2006, 1 (2) 193-208; DOI: 10.2215/CJN.00540705
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Epidemiology
    • Cause of HF in Diabetes and the “Toxic Triad”
    • Diabetes and Diastolic and Subclinical Systolic HF
    • Treatment
    • New Therapies
    • Conclusion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Assessing Physical Function and Physical Activity in Patients with CKD
  • Effect of Red Cell Transfusions on Future Kidney Transplantation
  • Management of Crush Victims in Mass Disasters: Highlights from Recently Published Recommendations
Show more In-Depth Reviews

Cited By...

  • Are targeted therapies for diabetic cardiomyopathy on the horizon?
  • Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?
  • Strain Imaging in Uncomplicated Type 1 Diabetes Patients for Risk Stratification: It Aint as "Sweet" as it Sounds
  • Epigenetic changes and alteration of Fbn1 and Col3A1 gene expression under hyperglycaemic and hyperinsulinaemic conditions
  • Cost-Effectiveness of Aliskiren in Type 2 Diabetes, Hypertension, and Albuminuria
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals
  • Wolters Kluwer Partnership

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire